<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01424111</url>
  </required_header>
  <id_info>
    <org_study_id>AMD-CS-0007</org_study_id>
    <nct_id>NCT01424111</nct_id>
  </id_info>
  <brief_title>Exploring Biomarkers for Depression</brief_title>
  <official_title>Exploring Biomarkers for Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyss Institute at Harvard University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Martinos Center for Biomedical Imaging</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wyss Institute at Harvard University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to explore objective biomarkers in voice, physiological,&#xD;
      motor, and brain imaging signals that may one day be used to complement clinical evaluation&#xD;
      and treatment of depression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis for our work is that dynamical fluctuations of biological signals, such as,&#xD;
      voice, video, pulse rate, oxygen saturation, skin temperature, skin conductivity, motor&#xD;
      response, magnetoencephalography (MEG), and electroencephalography (EEG), are less complex&#xD;
      during depressive than normal phases. There is a great need for objective biomarkers that may&#xD;
      complement current clinical measures to help recognize depression, monitor its severity, and&#xD;
      quantify the effect of interventions and recovery.&#xD;
&#xD;
      Data will be collected from 20 adult participants seeking outpatient treatment for depression&#xD;
      at the Depression and Clinical Research Program at Massachusetts General Hospital (MGH), each&#xD;
      participating for a total of approximately 9 weeks. For correlation of findings, data will&#xD;
      also be collected from 20 subjects who take part in the healthy/control group. The&#xD;
      healthy/control group will participate in a more limited study visit schedule over the course&#xD;
      of 9 weeks, and will not be given any treatment. During study visits, the investigators will&#xD;
      conduct recordings of voice, video, pulse rate, oxygen saturation, body temperature, skin&#xD;
      conductivity, and motor movement at the Department of Psychiatry at MGH. In addition, each&#xD;
      subject may participate in MEG, EEG, and Magnetic Resonance Imaging (MRI) brain imaging&#xD;
      sessions at the Athinoula A. Martinos Center for Biomedical Engineering.&#xD;
&#xD;
      In order to collect relevant data and correlate findings with accepted clinical measures of&#xD;
      depression severity and response to treatment, this study is conducted as a follow-up study&#xD;
      in concert with a typical drug treatment protocol for Major Depressive Disorder (MDD).&#xD;
      Specifically, our measurements will be made in conjunction with a standard of care drug&#xD;
      treatment protocol using the antidepressant medication escitalopram, an FDA-approved&#xD;
      selective serotonin re-uptake inhibitor (SSRI) commonly used to treat depression. The data&#xD;
      will be collected over a period of approximately 9 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">October 14, 2017</completion_date>
  <primary_completion_date type="Actual">October 14, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Biomarkers</measure>
    <time_frame>Participants will be followed for an expected average of 9 weeks of data collection.</time_frame>
    <description>Objective biomarkers in voice, physiological, motor and brain imaging signals</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">51</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <description>Those receiving an open-label, 10-20 mg/day, flexible-dose of escitalopram. The treatment period is 8 weeks long.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <description>Those not receiving treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>An open-label, 10-20 mg/day, flexible-dose of escitalopram will be administered to all subjects included in this study in the form of tablets. The treatment period is 8 weeks long.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Lexapro</other_name>
    <other_name>Cipralex</other_name>
    <other_name>Seroplex</other_name>
    <other_name>Lexamil</other_name>
    <other_name>Lexam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Healthy Control</intervention_name>
    <description>No Treatment</description>
    <arm_group_label>Healthy Control</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients seeking treatment for Major Depressive Disorder at the Depression Clinical and&#xD;
        Research Program at Massachusetts General Hospital. This study also enrolls a limited&#xD;
        number of healthy controls.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Treatment Group Inclusion Criteria:&#xD;
&#xD;
          1. Men or women age 18-65;&#xD;
&#xD;
          2. Written informed consent;&#xD;
&#xD;
          3. Meet DSM-IV criteria (by Structured Clinical Interview for DSM-IV - SCID-I/P) for&#xD;
             current major depressive episode (MDE);&#xD;
&#xD;
          4. Hamilton Rating Scale for Depression (HAM-D-17) baseline score â‰¥ 16.&#xD;
&#xD;
        Treatment Group Exclusion Criteria:&#xD;
&#xD;
          1. Subjects whose first language is not English;&#xD;
&#xD;
          2. In women, pregnancy, plans to conceive, or unwillingness to comply with birth control&#xD;
             requirements;&#xD;
&#xD;
          3. Subjects with a baseline Clinical Global Impressions-Severity score of 6 or 7;&#xD;
&#xD;
          4. Subjects with suicidal ideation where outpatient treatment is determined unsafe by the&#xD;
             clinician. These subjects will be immediately referred to appropriate clinical&#xD;
             treatment;&#xD;
&#xD;
          5. Serious or unstable medical illness, including cardiovascular, hepatic, renal,&#xD;
             respiratory, endocrine, neurologic or hematologic disease;&#xD;
&#xD;
          6. History of seizure disorder;&#xD;
&#xD;
          7. History or current diagnosis of the following DSM-IV psychiatric illness: organic&#xD;
             mental disorder, schizophrenia, schizoaffective disorder, delusional disorder,&#xD;
             psychotic disorders not otherwise specified, bipolar disorder, patients with mood&#xD;
             congruent or mood incongruent psychotic features, patients with substance dependence&#xD;
             disorders, including alcohol, active within the last 12 months;&#xD;
&#xD;
          8. Subjects with mood congruent or mood incongruent psychotic features;&#xD;
&#xD;
          9. Clinical or laboratory evidence of hypothyroidism;&#xD;
&#xD;
         10. Positive urine drug screen at evaluation visit;&#xD;
&#xD;
         11. Electro Convulsive Therapy (ECT) during the last year;&#xD;
&#xD;
         12. Subjects who have failed to respond during the course of their current major&#xD;
             depressive episode to a trial of escitalopram (at least 40mg/day for six weeks or&#xD;
             more)&#xD;
&#xD;
         13. History of intolerance to citalopram or escitalopram;&#xD;
&#xD;
         14. Subjects requiring excluded medications including antidepressants, anorexics,&#xD;
             antiarrhythmics, and other psychotropic agents (including lithium, benzodiazepine&#xD;
             sedatives, other sedatives, and anti-seizure medications), beta-blockers (such as&#xD;
             metoprolol or propranolol) ketoconazole, itraconazole, fluconazole, erythromycin,&#xD;
             omeprazole, cimetidine, dehydroepiandrosterone (DHEA), entacapone, hydroxytryptophan&#xD;
             (5-HTP), ginkgo, St. John's Wort (hypercium), naratriptan, rizatriptan, sibutramine,&#xD;
             zolmitriptan and warfarin (Coumadin).&#xD;
&#xD;
         15. Subjects who have failed two or more adequate antidepressant trials during the current&#xD;
             Major Depressive Episode (MDE)&#xD;
&#xD;
             If a subject is deemed eligible from the above criteria, there is additional exclusion&#xD;
             criteria required to participate in Martinos Center study visits, listed below.&#xD;
             Subjects meeting any of the below criteria will not be allowed to participate in&#xD;
             visits to the Martinos Center.&#xD;
&#xD;
         16. Subjects of weight above 300 lbs. (limit for 1.5T Siemens Sonata whole body scanner&#xD;
             used in MRI data acquisition);&#xD;
&#xD;
         17. History of significant head trauma (unconsciousness for 10 minutes or longer);&#xD;
&#xD;
         18. Surgical aneurysm clips;&#xD;
&#xD;
         19. Cardiac pacemaker;&#xD;
&#xD;
         20. Prosthetic heart valve;&#xD;
&#xD;
         21. Use of a neurostimulator;&#xD;
&#xD;
         22. Implanted pumps;&#xD;
&#xD;
         23. Cochlear implants;&#xD;
&#xD;
         24. Metal rods, plates, or screws in the body, or metal foil medical skin patches that&#xD;
             cannot be removed;&#xD;
&#xD;
         25. IUD;&#xD;
&#xD;
         26. Previous head surgery;&#xD;
&#xD;
         27. Hearing aid;&#xD;
&#xD;
         28. Non-removable dentures, root canals, dental implants, bridges, and wires in the mouth;&#xD;
&#xD;
         29. Currently breastfeeding;&#xD;
&#xD;
         30. Meniere's Disease;&#xD;
&#xD;
         31. Metal (shiny) tattoos or metal body jewelry that cannot be removed;&#xD;
&#xD;
         32. Claustrophobia;&#xD;
&#xD;
         33. Abnormal hearing;&#xD;
&#xD;
         34. Glasses with vision correction greater than +/- 6 diopters.&#xD;
&#xD;
        Healthy/Control Group Inclusion Criteria:&#xD;
&#xD;
          1. Men or Women, ages 18-65;&#xD;
&#xD;
          2. Written informed consent;&#xD;
&#xD;
          3. QIDS-SR score of &lt; 8 at Screening Visit;&#xD;
&#xD;
          4. Agrees to, and is eligible for, all biomarkers procedures (M/EEG, MRI, physiological&#xD;
             recordings);&#xD;
&#xD;
        Healthy/Control Group Exclusion Criteria:&#xD;
&#xD;
          1. Subjects whose first language is not English;&#xD;
&#xD;
          2. Current or lifetime history for major depressive disorder, psychotic depression&#xD;
             bipolar (I, II, or NOS) disorder, schizoaffective disorder, schizophrenia, or other&#xD;
             Axis I psychotic disorder;&#xD;
&#xD;
          3. Meet DSM-IV criteria (by Structured Clinical Interview for DSM-IV - SCID-I/P) for&#xD;
             current major depressive episode (MDE);&#xD;
&#xD;
          4. HAM-D-17 baseline score â‰¥ 8&#xD;
&#xD;
          5. Any current Axis I or Axis II diagnoses;&#xD;
&#xD;
          6. A woman who is pregnant or breastfeeding;&#xD;
&#xD;
          7. Meeting DSM-IV criteria for substance dependence in the last 6 months, except for&#xD;
             nicotine, or substance abuse in the last 2 months;&#xD;
&#xD;
          8. Positive urine drug screen at evaluation visit;&#xD;
&#xD;
          9. Any current history for an unstable general medical condition (GMC) that requires&#xD;
             hospitalization or deemed by investigator to be clinically significant;&#xD;
&#xD;
         10. Any current history for a moderate or severe acute or chronic medical condition that,&#xD;
             based on the judgment of the PI or appropriate medical personnel would exclude the&#xD;
             subject i.e. epilepsy, unstable hypothyroidism;&#xD;
&#xD;
             If a subject is deemed eligible from the above criteria, there is additional exclusion&#xD;
             criteria required to participate in Martinos Center study visits. Subjects meeting any&#xD;
             of the below criteria will not be allowed to participate in visits to the Martinos&#xD;
             Center:&#xD;
&#xD;
         11. Subjects of weight above 300 lbs. (limit for 1.5T Siemens Sonata whole body scanner&#xD;
             used in MRI data acquisition);&#xD;
&#xD;
         12. History of significant head trauma (unconsciousness for 10 minutes or longer);&#xD;
&#xD;
         13. Surgical aneurysm clips;&#xD;
&#xD;
         14. Cardiac pacemaker;&#xD;
&#xD;
         15. Prosthetic heart valve;&#xD;
&#xD;
         16. Use of a neurostimulator;&#xD;
&#xD;
         17. Implanted pumps;&#xD;
&#xD;
         18. Cochlear implants;&#xD;
&#xD;
         19. Metal rods, plates, or screws in the body, or metal foil medical skin patches that&#xD;
             cannot be removed;&#xD;
&#xD;
         20. IUD;&#xD;
&#xD;
         21. Previous head surgery;&#xD;
&#xD;
         22. Hearing aid;&#xD;
&#xD;
         23. Non-removable dentures, root canals, dental implants, bridges, and wires in the mouth;&#xD;
&#xD;
         24. Currently breastfeeding;&#xD;
&#xD;
         25. Meniere's Disease;&#xD;
&#xD;
         26. Metal (shiny) tattoos or metal body jewelry that cannot be removed;&#xD;
&#xD;
         27. Claustrophobia;&#xD;
&#xD;
         28. Abnormal hearing;&#xD;
&#xD;
         29. Glasses with vision correction greater than +/- 6 diopters.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Nierenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DCRP, Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diana Young, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wyss Institute, Harvard University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tommi Raij, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Martinos Center, Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Depression Clinical and Research Program, MGH</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>August 19, 2011</study_first_submitted>
  <study_first_submitted_qc>August 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2011</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Biomarkers</keyword>
  <keyword>Depression</keyword>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Escitalopram</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

